BioCentury
ARTICLE | Financial News

New IPO filings include NGM, Arog, Gamida

October 5, 2018 8:14 PM UTC

Three biotechs filed late Sept. 28 to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South San Francisco, Calif.), Arog Pharmaceuticals Inc. (Dallas, Tex.) and Gamida Cell Ltd. (Jerusalem, Israel) (see "Paper Chase").

NGM, a liver disease and metabolic company, filed to raise up to $75 million in a listing. Among the company's five clinical candidates, the most advanced, NGM282, is due to begin a Phase IIb trial in 1Q19 to treat non-alcoholic steatohepatitis (NASH). The listing's underwriters are Goldman Sachs, Citigroup and Cowen...